PARTNER 3 Trial: 1-year outcomes at a glance
PARTNER 3 Trial: 1-year outcomes at a glance

Demonstrating the superiority of SAPIEN 3 Transcatheter Aortic Valve Implantation (TAVI) compared with SAVR in low-risk patients with severe aortic stenosis. *,1

Download this infographic to read more about:
  • The study design
  • The primary and secondary endpoints
  • How younger patients may benefit from TAVI

*PARTNER 3 Trial proved SAPIEN 3 TAVI is superior to surgery on the primary endpoint (all-cause death, all stroke, and rehospitalisation) and multiple pre-specified secondary endpoints at one year. 


1    Mack MJ, Leon MB, Thourani VH, et al. N Engl J Med. 2019;380(18):1695–1705.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

PP—EU-4352 v1.0

Help us create better content with 3 short questions.

Content relating to is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.
Skip to content